ReviewPharmaceuticals (Basel, Switzerland)2010
Nitric Oxide Synthase Inhibitors as Antidepressants.
Review in Pharmaceuticals (Basel, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 94 citations in OpenAlex.
- Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.Psychopharmacology · 2018Trial
- The NO-cGMP signaling pathway and depression: mechanisms and therapeutic prospects.Molecular biology reports · 2026Review
- Probing the Molecular Mechanisms of Kratom's Antipsychotic Effects through a Multi-modal Computational Approach.Current pharmaceutical design · 2025Article
- Irisin alleviates chronic constriction injury-induced hyperalgesia and affective disorders in mice through NF-κB and Nrf2 signaling pathways.IBRO neuroscience reports · 2024Article
- Modulatory effect of olanzapine on neuronal nitric oxide synthase (nNOS) expression in the rat striatum.Journal of neural transmission (Vienna, Austria : 1996) · 2024Article
- Exploring the Roles of Vitamins C and D and Etifoxine in Combination with Citalopram in Depression/Anxiety Model: A Focus on ICAM-1, SIRT1 and Nitric Oxide.International journal of molecular sciences · 2024Article
- Unraveling the Potential of Isorhamnetin as an Adjuvant in Depression Treatment with Escitalopram.Current issues in molecular biology · 2023Article
- Antidepressant Like Effect of Ascorbic Acid in Mice: Possible Involvement of NO-sGC-cGMP Signaling.Neurochemical research · 2022Article
- Hydrogen Ion Dynamics as the Fundamental Link between Neurodegenerative Diseases and Cancer: Its Application to the Therapeutics of Neurodegenerative Diseases with Special Emphasis on Multiple Sclerosis.International journal of molecular sciences · 2022Review
- Possible involvement of NO-sGC-cGMP signaling in the antidepressant like effect of pyridoxine in mice.Metabolic brain disease · 2022Article
- Anti-depressant Effect of Betaine Mediates via Nitrergic and Serotoninergic Systems in Ovariectomized Mice.Archives of Razi Institute · 2021Article
- The role of brain gaseous neurotransmitters in anxiety.Pharmacological reports : PR · 2021Review
- Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.Translational psychiatry · 2021Article
- Plasma Metabolomics Profiling of Metabolic Pathways Affected by Major Depressive Disorder.Frontiers in psychiatry · 2021Article
- Curcumin in Depression: Potential Mechanisms of Action and Current Evidence-A Narrative Review.Frontiers in psychiatry · 2020Review
- Repeated Nitrous Oxide Exposure Exerts Antidepressant-Like Effects Through Neuronal Nitric Oxide Synthase Activation in the Medial Prefrontal Cortex.Frontiers in psychiatry · 2020Article
- Early-Life Stress Induces Depression-Like Behavior and Synaptic-Plasticity Changes in a Maternal Separation Rat Model: Gender Difference and Metabolomics Study.Frontiers in pharmacology · 2020Article
- Additive interaction between scopolamine and nitric oxide agents on immobility in the forced swim test but not exploratory activity in the hole-board.Psychopharmacology · 2019Article
- Neuronal nitric oxide synthase and affective disorders.IBRO reports · 2018Review
- Methylene blue and its analogues as antidepressant compounds.Metabolic brain disease · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Affective and anxiety disorders are widely distributed disorders with severe social and economic effects. Evidence is emphatic that effective treatment helps to restore function and quality of life. Due to the action of most modern antidepressant drugs, serotonergic mechanisms have traditionally been suggested to play major roles in the pathophysiology of mood and stress-related disorders. However, a few clinical and several pre-clinical studies, strongly suggest involvement of the nitric oxide (NO) signaling pathway in these disorders. Moreover, several of the conventional neurotransmitters, including serotonin, glutamate and GABA, are intimately regulated by NO, and distinct classes of antidepressants have been found to modulate the hippocampal NO level in vivo. The NO system is therefore a potential target for antidepressant and anxiolytic drug action in acute therapy as well as in prophylaxis. This paper reviews the effect of drugs modulating NO synthesis in anxiety and depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.